Related Experiment Video
Updated: Jul 1, 2026
08:49
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
11.1K
Recent Breakthroughs in Exosome-Based Drug Delivery: A Comprehensive Review for Cancer Therapy
Dhwani Shah1, Shweta Gandhi2, Shreeraj Shah1
1Department of Pharmaceutical Technology, L. J. Institute of Pharmacy, L. J. University, Ahmedabad, India.
Cancer Biotherapy & Radiopharmaceuticals
|June 12, 2025
Summary
Exosomes, natural nanoparticles, show promise for cancer drug delivery systems (DDSs). Plant-derived exosomes (PDEs) offer biocompatibility and anticancer effects, advancing personalized cancer therapies.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Exosomes, natural nanoparticles, are emerging as efficient drug delivery systems (DDSs) for cancer therapy.
- Plant-derived exosomes (PDEs) exhibit biocompatibility and low toxicity, enhancing DDS potential.
- PDEs demonstrate anticancer effects, addressing challenges like treatment resistance and variability.
Purpose of the Study:
- To review the latest advancements in exosome-mediated drug delivery for cancer treatment.
- To highlight the role and potential of plant-derived exosomes (PDEs) in cancer therapy.
- To discuss emerging trends, challenges, and future perspectives in exosome-based DDS.
Main Methods:
- Summarizing isolation techniques: ultracentrifugation and immunological isolation.
- Detailing exosome characterization parameters for formulation.
- Reviewing exosome-based DDS, with a focus on plant-derived exosomes (PDEs).
Main Results:
- Exosomes can transfer various therapeutic molecules across biological barriers.
- PDEs show significant potential in overcoming conventional treatment limitations.
- Nanotechnology and personalized medicine can enhance exosome-mediated cancer treatment efficacy and cost-effectiveness.
Conclusions:
- Exosome-based DDS, particularly those using PDEs, represent a promising frontier in oncology.
- Clinical applications are evolving, with ongoing research addressing scalability, purification, and regulatory hurdles.
- Further development is crucial for realizing the full potential of exosome-mediated cancer therapies.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:36Overview of Exosomes
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...